Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 2.74B | 2.78B | 3.00B | 1.70B | 1.66B | 534.89M |
Gross Profit | 1.25B | 1.29B | 1.49B | 1.28B | 1.35B | 320.81M |
EBITDA | 222.70M | -1.46B | 607.00M | 955.44M | 1.09B | 143.76M |
Net Income | -466.40M | -2.05B | -10.10M | 704.20M | 810.29M | 72.92M |
Balance Sheet | ||||||
Total Assets | 6.38B | 6.42B | 8.56B | 2.43B | 1.87B | 910.87M |
Cash, Cash Equivalents and Short-Term Investments | 151.70M | 98.30M | 167.30M | 828.50M | 489.94M | 52.77M |
Total Debt | 2.79B | 2.68B | 2.61B | 139.30M | 108.50M | 112.30M |
Total Liabilities | 3.59B | 3.44B | 3.56B | 501.00M | 538.46M | 351.05M |
Stockholders Equity | 2.79B | 2.98B | 5.01B | 1.93B | 1.33B | 559.82M |
Cash Flow | ||||||
Free Cash Flow | 123.30M | -112.10M | 70.90M | 513.14M | 564.84M | 107.26M |
Operating Cash Flow | 200.40M | 83.00M | 280.20M | 805.87M | 629.76M | 134.49M |
Investing Cash Flow | -183.60M | -149.90M | -187.60M | -319.53M | -63.32M | -27.23M |
Financing Cash Flow | 25.70M | 48.80M | -265.80M | -173.18M | -130.28M | -98.28M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
69 Neutral | $15.54B | 28.98 | 11.38% | ― | 1.28% | -17.73% | |
68 Neutral | $2.42B | 15.34 | 18.27% | ― | 0.91% | 45.81% | |
58 Neutral | $7.97B | 116.65 | -20.54% | ― | -8.36% | -669.36% | |
54 Neutral | $11.86B | 136.07 | -3.30% | 2.94% | -27.41% | 67.01% | |
52 Neutral | $1.91B | ― | -14.80% | ― | -3.00% | 76.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $1.24B | 55.81 | -25.55% | ― | -32.59% | -667.81% |
On August 21, 2025, QuidelOrtho Corporation completed a significant debt refinancing transaction, entering into a Credit Agreement with Bank of America and other lenders. This agreement includes a $1.15 billion senior secured term loan A, a $100 million delayed draw term loan A, a $1.45 billion senior secured term loan B, and a $700 million revolving credit facility. The refinancing allows QuidelOrtho to extend its debt maturities, reduce required amortization payments, and improve financial flexibility, supporting future growth and strengthening its capital structure.